Oncolytic Virotherapy: Volume III

Given the success of Volume I and Volume II of this Research Topic, and how rapid the subject area is evolving, we are pleased to announce the launch of Oncolytic Virotherapy - Volume III.

Using viruses to treat cancer is an established concept, and many viruses have shown promising anti-tumor efficacies. Oncolytic viruses are safe and well-characterized pathogens with a stable genome. The outstanding clinical results for oncolytic virotherapy deserve serious attention and consideration to make it a treatment option alongside classical cancer therapeutics. Virotherapy uses replication-competent oncolytic viruses to replicate and destroy cancer cells selectively. The transformed nature of cancer cells offers a permissive environment for some viruses’ replication and to complement viral mutations. The in situ amplification and spread within the tumor mass is the key benefit of such replication-competent viruses. Oncolytic virotherapy is divided into two main groups, according to tumor specificity: naturally oncolytic viruses to replicate in human cancer cells; and gene-modified viruses engineered to accomplish selective oncolysis.

In this Research Topic, we are looking for improving of cancer therapeutics through spotting the light on the novel, innovative manuscripts about recent and promising research on oncolytic virotherapy and ways to enhance its efficacy against cancer and related applications. We welcome preclinical in vitro and in vivo research work, translational research, and clinical studies.

We welcome the submissions of original research and review articles covering, but not limited to, the following sub-topics:

• Viro-immunotherapy

• Combination Therapeutics

• Nano-virotherapy

• Armed therapeutic viruses

• Reprogrammed viruses for cancer targeting

• Tumor imaging using oncolytic viruses

• Cancer-Targeting gene-viro-therapy

• Modeling the efficacy of oncolytic viruses in vitro and in vivo